XIX International AIDS Conference


WEAB02 HPV: Meeting the Global Challenge
  Oral Abstract Session : Track B
Venue: Session Room 3
Time: 25.07.2012, 14:30 - 16:00
Co-Chairs: Kathryn Anastos, United States
Tim Wilkin, United States
 
 

14:30
WEAB0201
Confronting the challenge of HPV in resource-limited settings


C. Firnhaber, South Africa

14:50
WEAB0202
Abstract
Powerpoint
Webcast
Immunogenicity of the HPV-6, -11, -16, -18 vaccine in HIV-positive young women
J. Kahn1, J. Xu2, B. Kapogiannis3, B. Rudy4, N. Liu2, R. Gonin2, C. Wilson5, C. Worrell3, K. Squires6
1Cincinnati Children's Hospital Medical Center, Pediatrics, Cincinnati, United States, 2Westat Inc., Rockville, United States, 3NICHD/PAMAB, Rockville, United States, 4New York University, New York, United States, 5University of Alabama at Birmingham - School of Public Health, Birmingham, United States, 6Jefferson Medical College, Philadelphia, United States
J. Kahn, United States

15:05
WEAB0203
Abstract
Powerpoint
Webcast
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-positive women
E.M. Kojic1, M. Cespedes2, T. Umbleja3, M. Kang3, J. Aberg2, R. Allen4, B. Grinsztein5, C. Firnhaber6, J. Webster-Cyriaque7, J.M. Palefsky8, C. Godfrey9, A.J. Saah10, S. Cu-Uvin1, ACTG 5240 Study Group
1Brown University - The Miriam Hospital, Infectious Diseases, Providence, United States, 2New York School of Medicine, New York, United States, 3Harvard School of Public Health, Boston, United States, 4ACTG Operations Center, Silver Spring, United States, 5Chagas Fiocruz, Rio de Janeiro, Brazil, 6University of Witwatersrand, Johannesburg, South Africa, 7University of North Carolina, Chapel Hill, United States, 8University of California at San Francisco, San Francisco, United States, 9NIAID NIH, Bethesda, United States, 10Merck Research Labs, North Wales, United States
M. Cespedes, United States

15:20
WEAB0204
Abstract
Powerpoint
Webcast
HPV genotype attribution of anal neoplasia in HIV-positive MSM: estimating the preventable fraction and disease misclassification
V. Sahasrabuddhe1, P. Castle2, S. Follansbee3, S. Borgonovo3, B. LaMere3, D. Tokugawa3, T. Darragh4, S. Boyle5, M. Sadorra5, S. Tang5, N. Wentzensen1
1National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, United States, 2American Society for Clinical Pathology, Washington, United States, 3Kaiser Permanente Northern California, San Francisco, United States, 4University of California at San Francisco, San Francisco, United States, 5Roche Molecular Systems, Pleasanton, United States
V. Sahasrabuddhe, United States

15:35
WEAB0205
HPV vaccine: the beginning of the end or the end of the beginning


D. Money, Canada

Powerpoints presentations
Immunogenicity of the HPV-6, -11, -16, -18 vaccine in HIV-positive young women - Jessica Kahn

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-infected women - Michelle Cespedes

HPV genotype attribution of anal neoplasia in HIV-positive MSM: estimating the preventable fraction and disease misclassification - Vikrant Sahasrabuddhe



Rapporteur report

Track B report by Dr. Omar Sued


Dr Firnhaber reviewed the impact of HPV in low resources areas. In HIV women, high risk HPV can be found in 40-80%. Advanced immunosuppression increases the detection of HPV, the presence of dysplasia, progression rate and the failure to clearance the infection. HAART delays progression of lesions and improve the clearance rates of HPV infection. Regarding to anal HPV disease in MSM-HIV, limited information shows a 40% of prevalence and 30% of high grade anal dysplasia were presented.

The two next presentations were on HPV vaccine studies in HIV women. In both studies the vaccine was safe and well tolerated and patients seronegatives at baseline showed almost 100% of seroconversion rate for most of the HPV types (although for HPV was 85%). Protection improved also in women positive at baseline. Only a minimal part (only 4% in the ACTG 5240 study) were seropositive for all types contained in the vaccine).

A study for estimating the prevention of HPV with vaccine in HIV MSM was presented, using data of a cross sectional survey involving 363 HIV positive MSM including anal samples for HPV testing and cytology, high resolution anoscopy and biopsy. Almost all patients had HPV (any, 94.4%, carcinogenic HPV 75%), 110/342 had AIN2 or AIN3 and only 92 had normal anoscopy. The attribution model estimated in 40-70% the potential protective effect of a quadrivalent vaccine in MSM patients.

Dr Money closed the session summarizing the current global situation, the barriers for screening and vaccination programs, the new screening options and recent advances. More research should be done in HPV vaccines, including the potential “therapeutic effects” of efficacy in males and PLWHA, and simpler vaccine schedules.




   

    The organizers reserve the right to amend the programme.


Contact Us | Site map © 2012 International AIDS Society